Category Archives: Sec 3 (d)

“Indian CSO letter to the DPIIT on the proposed amendment to the Patent Rules”

Posted on May 20, 2019 by donttradeourlivesaway

20th May, 2019   New Delhi 16 May 2019 To Shri Ramesh Abhishek Secretary, Department for Promotion of Industry and Internal Trade, Ministry of Commerce & Industry, Room No.157 Udyog Bhawan, New Delhi Telephone : 2306 1815, 2306 1667, 23061598(F) … Continue reading →

Posted in Fast track patent examination, Indian Patent Law, Patent examination system, Sec 3 (d) | Leave a comment

People living with hepatitis C and HIV challenge evergreening patents on lifesaving hepatitis C drugs in India

Posted on July 10, 2018 by donttradeourlivesaway

New Delhi, 10 July 2018: Delhi Network of Positive People (DNP+) has filed today two patent oppositions before the Indian patent office, challenging additional patent claims by US pharmaceutical corporation-Gilead Sciences for the hepatitis C medicines sofosbuvir and velpatasvir. These … Continue reading →

Posted in Drug prices, Hepatitis C, Indian Patent Law, Patent, Patent Opposition, Sec 3 (d) | Tagged , | Leave a comment

Five years after the Indian Supreme Court’s novartis verdict

Posted on May 31, 2018 by donttradeourlivesaway

Source: Intellectual Property Watch | May 21, 2018 On 1 April 2013, in a packed room inside India’s Supreme Court, a magnificent building in Indo-British architectural style, two judges delivered a verdict that impacted the national and global conversation about … Continue reading →

Posted in Novartis Case, Sec 3 (d) | Leave a comment

Weed out evergreen patents

Posted on May 30, 2018 by donttradeourlivesaway

Source: Live Law | May 27, 2018 A recently published report “Pharmaceutical Patent Grants in India: How our safeguards against evergreening have failed and why the system must be reformed“, by Dr. Feroz Ali, Dr. Sudarsan Rajagopal, Dr. Venkata S. … Continue reading →

Posted in Evergreening, Patents, Sec 3 (d) | Leave a comment

Rampant evergreening in Indian pharma industry

Posted on April 27, 2018 by donttradeourlivesaway

Source: live mint | April 27, 2018 Pharmaceutical companies commonly used legal argument, as opposed to demonstrating proof of therapeutic efficacy, to overcome anti-evergreening objections India has been at the forefront of developing an alternative model of patent law which … Continue reading →

Posted in Indian Patent Law, Indian Patent Office, Sec 3 (d), Uncategorized | Leave a comment

72% of drug patent grants in India for marginal improvements, says study

Posted on April 26, 2018 by donttradeourlivesaway

Source: Business Today | April 25, 2018 Majority of pharmaceutical drug patents granted by India might have skipped elaborate scrutiny, an analysis of patent grants by a team of researchers and patent lawyers reveals.   The report which studied the prosecution … Continue reading →

Posted in Indian Patent Office, Patent, Patent Enforcement, Patents, Sec 3 (d) | Leave a comment

An Access Regime based on Indian Patents Act -Review Of “The Access Regime” by Feroz Ali

Posted on July 20, 2017 by donttradeourlivesaway

Source: LiveLaw.in Even though the Agreement on the trade-related aspects of intellectual property rights (TRIPS) set the minimum standards of protection and enforcement of intellectual property (IP) rights, it could not harmonise the various national patent laws. Irrespective of the … Continue reading →

Posted in Compulsory Licensing, FTA, Patent Opposition, Sec 3 (d), TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment

A trade pact that could hit India hard

Posted on May 29, 2017 by donttradeourlivesaway

By Ranja Sengupta, The Hindu BusinessLine There’s a rush to finalise RCEP this year. India is being pushed into covering most tariff lines, which will destroy its economy There was clearly huge pressure on India to conclude negotiations this year … Continue reading →

Posted in IP Rights, IPR Enforcement, Regional Comprehensive Economic Partnership, Sec 3 (d), Uncategorized | Leave a comment

US continue to bully India – Place India again in Special 301 Priority Watch List 2017

Posted on May 4, 2017 by donttradeourlivesaway

Yet again, USTR places India on its Priority Watch List in Special report 301 stating the lack of sufficient measurable improvements to its IP framework that negatively affects U.S. right holders across the world.  It points out that India support … Continue reading →

Posted in Sec 3 (d), Special 301 report, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized, USTR, USTR 301 report | Leave a comment

India–EFTA trade talks may make medicines more expensive

Posted on March 22, 2017 by donttradeourlivesaway

MSF and civil society urge Swiss negotiators not to undermine the ‘pharmacy of the developing world’   Geneva/New Delhi, 22March 2017 – Asintellectual property (IP) negotiators from India andthe four countries from EFTA (European Free Trade Association) meeting New Delhi … Continue reading →

Posted in Data Exclusivity, EFTA-India FTA, Evergreening, Patent, Sec 3 (d), Uncategorized | Leave a comment